Cerebral atrophy, apolipoprotein E ɛ4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment
Abstract
Patients with amnestic mild cognitive impairment (MCI) demonstrate decline in everyday function. In this study, we investigated whether whole brain atrophy and apolipoprotein E (APOE) genotype are associated with the rate of functional decline in MCI.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2010
- Source ID
- 10.1016/j.jalz.2010.02.003
Entities
People
- Beth A. Jerskey
- Brian R. Ott
- Geoffrey Tremont
- Lawrence H. Sweet
- Michael L Alosco
- Ozioma C. Okonkwo
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- Alzheimer's Association
- Bristol-Myers Squibb
- Brown University
- Chiron Corporation
- Eli Lilly and Company
- Forest Laboratories
- GSK
- Johns Hopkins University
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- Rhode Island Hospital